Blog
Something inspiring would go here to explain the blog.
-
Innovative medicines as drivers of economic security – A strategic imperative for G7 economies
By
Why This Matters: Innovative medicines are engines of economic growth and security but without sustained focus and commitment to the sector, we risk losing future scientific progress. David Reddy, Director General
-
Canada’s Wait for New Medicines Is Long – and About to Get Longer
By
Why This Matters: Canada already makes patients wait too long for new medicines. Global drug policy changes could make things worse. Canadians already have the longest wait in the G7
-
Enabling Innovation: The R&D Ecosystem for Medicines and Vaccines
By
Why This Matters: A strong research and development ecosystem is essential to driving medical innovation, supporting economic growth, and ensuring Canadians can benefit from the next generation of medicines. Investment
-
Canada’s Innovation Gap: Why Your Access to Medicines is at Risk
By
Why This Matters: Canada is falling behind in providing timely access to life-saving medications, but there is a critical opportunity to build a more resilient and competitive healthcare system. Dr.
-
Nine in Ten Canadians Call for Widespread Health System Change in New Nanos Research Survey
By
Why This Matters: National polling shows thatCanadians are ready to embrace healthcare reform, calling on decision-makers for practical policy changes so proven innovations can reach Canadians faster and more equitably. A
-
Most Favored Nation Drug Pricing: Analysis and Implications
By
Why This Matters: As countries compete to attract research investment and secure early access to innovative medicines, understanding global pricing dynamics is critical to protecting Canada’s health future. This article
-
Walking a tightrope: Navigating US most-favored-nation prescription drug pricing in Canada
By
Why This Matters: As global markets adjust their drug policies, Canada faces growing competition for pharmaceutical investment and innovation. Understanding how these global drug policies interact with Canada’s domestic health
-
Medtech Canada advocates for “zero for-zero” tariffs to safeguard affordability and supply of medical technologies in Canadian health care
By
Why This Matters: Tariffs on medical technologies can drive up healthcare costs, limit the availability of essential equipment, and delay care for patients who need timely treatment. Keeping these products
-
‘An urgent public health crisis:’ Why so many people are struggling to get medicine
By
Why This Matters: When global supply chains falter, Canadian patients can face drug delays or cost increases. A resilient system means better access, less disruption, and fewer surprises in care.
-
Think Tank Calls on Ottawa to Abandon Single-payer Pharmacare Model
By
Why This Matters: A pharmacare model that removes existing coverage could leave many Canadians without the medicines they currently rely on. Canadians deserve a system that expands access, not one